tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TVTX Stock Latest News

Promising Outlook for Travere Therapeutics: Buy Rating Affirmed on Anticipated FILSPARI Approval and Strategic Initiatives
RatingsPromising Outlook for Travere Therapeutics: Buy Rating Affirmed on Anticipated FILSPARI Approval and Strategic Initiatives
14h ago
TVTX
Ligand initiated with a Buy at Citi
PremiumThe Fly
Ligand initiated with a Buy at Citi
7d ago
LGND
TVTX
Positive Outlook for Travere Therapeutics: Buy Rating Backed by Strong Clinical Data and Market Expansion Potential
PremiumRatings
Positive Outlook for Travere Therapeutics: Buy Rating Backed by Strong Clinical Data and Market Expansion Potential
18d ago
TVTX
Optimistic Buy Rating for Travere Therapeutics Driven by Filspari’s Market Potential and Strategic Positioning
PremiumRatings
Optimistic Buy Rating for Travere Therapeutics Driven by Filspari’s Market Potential and Strategic Positioning
1M ago
TVTX
Positive Outlook for Travere Therapeutics: FILSPARI’s Advancements in Reducing Proteinuria and Long-term Kidney Failure Risk
PremiumRatings
Positive Outlook for Travere Therapeutics: FILSPARI’s Advancements in Reducing Proteinuria and Long-term Kidney Failure Risk
1M ago
TVTX
Travere Therapeutics announces data from Phase 3 DUPLEX study of FILSPARI
PremiumThe FlyTravere Therapeutics announces data from Phase 3 DUPLEX study of FILSPARI
1M ago
TVTX
Travere Therapeutics price target raised to $35 from $26 at Piper Sandler
Premium
The Fly
Travere Therapeutics price target raised to $35 from $26 at Piper Sandler
1M ago
TVTX
Promising Outlook for Travere Therapeutics: Buy Rating Affirmed on Strong Product Demand and Strategic Growth Potential
Premium
Ratings
Promising Outlook for Travere Therapeutics: Buy Rating Affirmed on Strong Product Demand and Strategic Growth Potential
1M ago
TVTX
Travere Therapeutics’ Strong Quarter and Future Prospects
PremiumCompany Announcements
Travere Therapeutics’ Strong Quarter and Future Prospects
2M ago
TVTX
Citi ups Travere target, opens ‘upside 90-day catalyst watch’
PremiumThe Fly
Citi ups Travere target, opens ‘upside 90-day catalyst watch’
2M ago
TVTX
Travere Therapeutics price target raised to $40 from $30 at TD Cowen
PremiumThe Fly
Travere Therapeutics price target raised to $40 from $30 at TD Cowen
2M ago
TVTX
Buy Rating Affirmed: Travere Therapeutics Surpasses Expectations with Strong Financial Performance and Strategic Milestones
PremiumRatings
Buy Rating Affirmed: Travere Therapeutics Surpasses Expectations with Strong Financial Performance and Strategic Milestones
2M ago
TVTX
Travere Therapeutics Reports Strong Q3 2025 Growth
PremiumCompany AnnouncementsTravere Therapeutics Reports Strong Q3 2025 Growth
2M ago
TVTX
Strong Buy Recommendation for Travere Therapeutics: Impressive Sales Growth and Strategic Positioning Highlight Future Potential
Premium
Ratings
Strong Buy Recommendation for Travere Therapeutics: Impressive Sales Growth and Strategic Positioning Highlight Future Potential
2M ago
TVTX
Closing Bell Movers: Amazon soars to all-time highs on earnings
Premium
The Fly
Closing Bell Movers: Amazon soars to all-time highs on earnings
2M ago
Z
EW
Travere Therapeutics reports Q3 EPS 29c, consensus (9c)
PremiumThe Fly
Travere Therapeutics reports Q3 EPS 29c, consensus (9c)
2M ago
TVTX
Is TVTX a Buy, Before Earnings?
PremiumPre-Earnings
Is TVTX a Buy, Before Earnings?
2M ago
TVTX
Travere Therapeutics’ Sparsentan Study: A Potential Game-Changer in Kidney Transplant Treatment
PremiumCompany Announcements
Travere Therapeutics’ Sparsentan Study: A Potential Game-Changer in Kidney Transplant Treatment
2M ago
TVTX
Travere Therapeutics Advances Sparsentan Study in Pediatric Kidney Diseases
PremiumCompany Announcements
Travere Therapeutics Advances Sparsentan Study in Pediatric Kidney Diseases
2M ago
TVTX
Travere Therapeutics Advances Phase 3 Study for Rare Genetic Disorder Treatment
PremiumCompany AnnouncementsTravere Therapeutics Advances Phase 3 Study for Rare Genetic Disorder Treatment
2M ago
TVTX
Travere Therapeutics’ Study on Homocystinuria: A Closer Look at the ACAPPELLA Study
Premium
Company Announcements
Travere Therapeutics’ Study on Homocystinuria: A Closer Look at the ACAPPELLA Study
2M ago
TVTX
Travere Therapeutics to present abstracts at ASN Kidney Week
Premium
The Fly
Travere Therapeutics to present abstracts at ASN Kidney Week
2M ago
TVTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >